dalteparin has been researched along with Cirrhoses, Experimental Liver in 7 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to examine the effect of the antithrombotic drugs aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of liver cirrhosis and to determine if these two drugs are beneficial in animals with advanced fibrosis or with established cirrhosis undergoing partial hepatectomy." | 7.74 | The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis. ( Assy, N; Hussein, O; Khalil, A; Luder, A; Paizi, M; Spira, G; Szvalb, S, 2007) |
| "The aim of this study was to examine the effect of the antithrombotic drugs aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of liver cirrhosis and to determine if these two drugs are beneficial in animals with advanced fibrosis or with established cirrhosis undergoing partial hepatectomy." | 3.74 | The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis. ( Assy, N; Hussein, O; Khalil, A; Luder, A; Paizi, M; Spira, G; Szvalb, S, 2007) |
| "Thioacetamide (TAA) was used to induce liver fibrosis in the model group." | 1.46 | Effects of aspirin and enoxaparin in a rat model of liver fibrosis. ( Li, CJ; Liu, DL; Shi, XL; Yang, ZH, 2017) |
| "Dalteparin sodium (DS) is a low-molecular-weight heparin with a mean molecular weight of 5,000." | 1.32 | Dalteparin sodium prevents liver injury due to lipopolysaccharide in rat through suppression of tumor necrosis factor-alpha production by Kupffer cells. ( Enomoto, N; Hirose, M; Ikejima, K; Kitamura, T; Sato, N; Takei, Y; Tsukada, S, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fortea, JI | 1 |
| Zipprich, A | 1 |
| Fernandez-Mena, C | 1 |
| Puerto, M | 1 |
| Bosoi, CR | 1 |
| Almagro, J | 1 |
| Hollenbach, M | 1 |
| Bañares, J | 1 |
| Rodríguez-Sánchez, B | 1 |
| Cercenado, E | 1 |
| Clément, MA | 1 |
| Rose, CF | 1 |
| Bañares, R | 1 |
| Vaquero, J | 1 |
| Ripoll, C | 1 |
| Li, CJ | 1 |
| Yang, ZH | 1 |
| Shi, XL | 1 |
| Liu, DL | 1 |
| Cerini, F | 1 |
| Vilaseca, M | 1 |
| Lafoz, E | 1 |
| García-Irigoyen, O | 1 |
| García-Calderó, H | 1 |
| Tripathi, DM | 1 |
| Avila, M | 1 |
| Reverter, JC | 1 |
| Bosch, J | 1 |
| Gracia-Sancho, J | 1 |
| García-Pagán, JC | 1 |
| Xu, M | 1 |
| Xue, W | 1 |
| Ma, Z | 1 |
| Bai, J | 1 |
| Wu, S | 1 |
| Assy, N | 1 |
| Hussein, O | 1 |
| Khalil, A | 1 |
| Luder, A | 1 |
| Szvalb, S | 1 |
| Paizi, M | 1 |
| Spira, G | 1 |
| Tsukada, S | 1 |
| Enomoto, N | 2 |
| Takei, Y | 2 |
| Hirose, M | 1 |
| Ikejima, K | 2 |
| Kitamura, T | 2 |
| Sato, N | 2 |
| Abe, W | 1 |
| Lang, T | 1 |
| Okumura, K | 1 |
7 other studies available for dalteparin and Cirrhoses, Experimental Liver
| Article | Year |
|---|---|
Enoxaparin does not ameliorate liver fibrosis or portal hypertension in rats with advanced cirrhosis.
Topics: Animals; Anticoagulants; Bacterial Translocation; Biomarkers; Blood Coagulation; Chemical and Drug I | 2018 |
Effects of aspirin and enoxaparin in a rat model of liver fibrosis.
Topics: Animals; Antithrombins; Aspirin; Disease Models, Animal; Enoxaparin; Liver; Liver Cirrhosis, Experim | 2017 |
Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
Topics: Animals; Enoxaparin; Liver Cirrhosis, Experimental; Male; Portal Pressure; Rats; Rats, Wistar; Vascu | 2016 |
Resveratrol Reduces the Incidence of Portal Vein System Thrombosis after Splenectomy in a Rat Fibrosis Model.
Topics: Animals; Anticoagulants; Apoptosis; Blood Platelets; Enoxaparin; Fibrinolytic Agents; Liver Cirrhosi | 2016 |
The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis.
Topics: Animals; Aspartate Aminotransferases; Aspirin; Bilirubin; Disease Progression; Enoxaparin; Fibrinoly | 2007 |
Dalteparin sodium prevents liver injury due to lipopolysaccharide in rat through suppression of tumor necrosis factor-alpha production by Kupffer cells.
Topics: Animals; Calcium; Cells, Cultured; Dalteparin; Female; Fibrinolytic Agents; Injections, Intraperiton | 2003 |
Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat.
Topics: Actins; Animals; Carbon Tetrachloride; Collagen Type I; Collagen Type I, alpha 1 Chain; Dalteparin; | 2007 |